Hepion director buys 1,250,000 company shares

Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share.

Rhea-AI Filing Summary

Hepion Pharmaceuticals director Appajosyula Sireesh bought 1,250,000 shares of common stock in an open-market transaction at $0.04 per share. Following this purchase on April 21, 2026, he holds 1,250,000 shares directly, indicating a newly established reported ownership position.

Insider Trade Summary

Net Buyer: 1,250,000 shares

Net Buy 1 txn

Insider Appajosyula Sireesh

Role Director

Bought 1,250,000 shs ($50K)

Type	Security	Shares	Price	Value
Purchase	Common Stock, par value $0.0001 per share	1,250,000	$0.04	$50K

Holdings After Transaction: Common Stock, par value $0.0001 per share — 1,250,000 shares (Direct)

Key Figures

Shares purchased: 1,250,000 shares Purchase price: $0.04 per share Shares owned after trade: 1,250,000 shares +1 more

4 metrics

Shares purchased 1,250,000 shares Open-market buy on April 21, 2026

Purchase price $0.04 per share Common Stock, par value $0.0001 per share

Shares owned after trade 1,250,000 shares Total direct holdings following transaction

Net buy shares 1,250,000 shares Net-buy direction in transaction summary

Key Terms

Form 4, open-market purchase, Common Stock, par value $0.0001 per share, beneficial ownership

4 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

open-market purchase financial

"transaction_action: "open-market purchase""

An open-market purchase is when an investor or a company buys shares on a public stock exchange at the going market price, rather than through a private deal. It matters to investors because these purchases change how many shares are available, can push the stock price up or signal confidence from large buyers, and often affect per-share metrics like earnings—think of it like someone buying lots of apples off a grocery shelf, reducing supply and potentially raising the price.

Common Stock, par value $0.0001 per share financial

"security_title: "Common Stock, par value $0.0001 per share""

beneficial ownership regulatory

"They may indicate any disclaimers of beneficial ownership"

Beneficial ownership means the person or entity that actually enjoys the benefits of owning shares or other assets — such as receiving dividends, voting rights, or price gains — even if the legal title is held in another name. For investors it matters because knowing who truly controls and profits from a company reveals who can influence decisions, exposes potential conflicts of interest or hidden concentration of power, and affects transparency and risk in the stock.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Hepion Pharmaceuticals (HEPA) disclose?

Hepion Pharmaceuticals reported that director Appajosyula Sireesh executed an open-market purchase of 1,250,000 shares of common stock at $0.04 per share, establishing direct ownership of 1,250,000 shares after the transaction.

Who is the insider involved in the latest Hepion Pharmaceuticals (HEPA) Form 4?

The insider is director Appajosyula Sireesh. He filed a Form 4 showing an open-market purchase of 1,250,000 Hepion Pharmaceuticals common shares at $0.04, resulting in direct ownership of 1,250,000 shares after the reported transaction.

How many Hepion Pharmaceuticals (HEPA) shares did the director buy and at what price?

Director Appajosyula Sireesh bought 1,250,000 shares of Hepion Pharmaceuticals common stock in an open-market transaction at $0.04 per share, according to the Form 4 insider trading report filed for April 21, 2026.

What is the director’s Hepion Pharmaceuticals (HEPA) ownership after this Form 4 trade?

After the reported open-market purchase, director Appajosyula Sireesh directly owns 1,250,000 shares of Hepion Pharmaceuticals common stock. The Form 4 shows this as his total direct holdings following the April 21, 2026 transaction.

Was the recent Hepion Pharmaceuticals (HEPA) insider trade a buy or a sell?

The transaction was a buy. The Form 4 lists transaction code “P” and describes an open-market purchase of 1,250,000 Hepion Pharmaceuticals common shares at $0.04 per share by director Appajosyula Sireesh.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 04/27/2026 - 06:24 AM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Appajosyula Sireesh

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
04/21/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, par value $0.0001 per share	04/21/2026		P		1,250,000	A	$0.04	1,250,000	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	/s/ Sireesh Appajosyula	04/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)